Loading..

Dynavax Technologies Corporation (DVAX) Report Analysis

Corporate Events

Neutral

Dynavax Technologies Corporation has filed a Sh...

2022-06-02 00:00:00

Dynavax Technologies Corporation has filed a Shelf Registration in the amount of $178.8 million. Security Name: Common Stock Securities Of...

Neutral

Dynavax Technologies Corporation Presents at Wi...

2022-05-25 20:05:00

Dynavax Technologies Corporation Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-06-2022 05:40 PM. Venue: Loews Chic...

Positive

Dynavax Technologies Corporation(NasdaqCM:DVAX)...

2022-05-17 00:00:00

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P Composite 1500

Positive

Dynavax Technologies Corporation(NasdaqCM:DVAX)...

2022-05-17 00:00:00

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P 600 Health Care (Sector)

Positive

Dynavax Technologies Corporation(NasdaqCM:DVAX)...

2022-05-17 00:00:00

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P 1000

Positive

Dynavax Technologies Corporation(NasdaqCM:DVAX)...

2022-05-17 00:00:00

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P 600

Neutral

Dynavax Technologies Corporation Presents at H....

2022-05-16 20:10:00

Dynavax Technologies Corporation Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Mia...

Neutral

Dynavax Technologies Corporation Reaffirms Earn...

2022-05-05 20:05:00

Dynavax Technologies Corporation reaffirmed earnings guidance for the year 2022. For the full-year CpG 1018 adjuvant net product revenues of a...

Neutral

Dynavax Technologies Corporation to Report Q1, ...

2022-04-21 20:05:00

Dynavax Technologies Corporation announced that they will report Q1, 2022 results After-Market on May 05, 2022

Neutral

Dynavax Technologies Corporation, Q1 2022 Earni...

2022-04-21 20:05:00

Dynavax Technologies Corporation, Q1 2022 Earnings Call, May 05, 2022

Neutral

Dynavax Technologies Corporation - Shareholder/...

2022-04-14 20:17:00

AGM

Neutral

Dynavax Technologies Corporation, Annual Genera...

2022-04-14 20:17:00

Dynavax Technologies Corporation, Annual General Meeting, May 26, 2022, at 09:00 Pacific Standard Time. Agenda: To elect our five nominees for...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

William Blair & Company, L.L.C., William Blair’...

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chi...

Negative

Dynavax Technologies Corporation Announces Appo...

2021-12-14 13:10:00

Dynavax Technologies Corporation announced the appointment of Elaine Sun to its Board of Directors. Ms. Sun has more than two decades of exper...

Neutral

Dynavax Technologies Corporation Presents at 4t...

2021-11-18 21:10:00

Dynavax Technologies Corporation Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 02:40 PM. Speakers: Ryan Spenc...

Neutral

Dynavax Technologies Corporation Provides Reven...

2021-11-04 20:50:00

Dynavax Technologies Corporation provided revenue guidance for the full year 2021. For the period, the company expects revenue guidance to be ...

Negative

Dynavax Technologies Corporation Announces Boar...

2021-10-21 20:20:00

Dynavax Technologies Corporation announced the appointment of Scott Myers to its Board of Directors. Mr. Myers was also elected Board Chairman...

Neutral

Dynavax Technologies Corporation to Report Q3, ...

2021-10-21 12:00:00

Dynavax Technologies Corporation announced that they will report Q3, 2021 results After-Market on Nov 04, 2021

Neutral

Dynavax Technologies Corporation, Q3 2021 Earni...

2021-10-21 12:00:00

Dynavax Technologies Corporation, Q3 2021 Earnings Call, Nov 04, 2021

Neutral

Dynavax Technologies Corporation Presents at AA...

2021-10-15 04:09:00

Dynavax Technologies Corporation Presents at AASLD The Liver Meeting, Nov-12-2021 . Speakers: Kelvin McKoy.

Neutral

Dynavax and U.S. Department of Defense Announce...

2021-10-04 12:00:00

Dynavax Technologies Corporation announced Dynavax has executed an agreement for approximately $22 million over two and a half years to develo...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright 2nd...

2021-09-27 20:20:00

H.C. Wainwright & Co., LLC, H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct 13, 2021.

Neutral

Dynavax Technologies Corporation Presents at Gu...

2021-09-27 20:20:00

Dynavax Technologies Corporation Presents at Guggenheim 2nd Annual Vaccine and Infectious Disease Days, Oct-05-2021 12:00 PM.

Neutral

Dynavax Technologies Corporation Presents at H....

2021-09-27 20:20:00

Dynavax Technologies Corporation Presents at H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct-13-2021 12:00 PM.

Neutral

Dynavax Technologies Corporation Presents at Ca...

2021-09-23 22:02:00

Dynavax Technologies Corporation Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 12:00 PM. Venue: New York, United States. S...

Neutral

COVID-19 Vaccine Developed by Clover Biopharmac...

2021-09-22 11:08:00

Dynavax Technologies Corporation announced that Clover Biopharmaceuticals (Clover) reported positive data for their protein-based COVID-19 vac...

Neutral

American Association For The Study Of Liver Dis...

2021-09-20 00:00:00

American Association For The Study Of Liver Diseases, AASLD The Liver Meeting, Nov 12, 2021 through Nov 15, 2021.

Neutral

Dynavax Technologies Corporation Presents at H....

2021-09-10 02:36:00

Dynavax Technologies Corporation Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New ...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

Medigen Vaccine Biologics Corporation and Dynav...

2021-08-23 12:00:00

Medigen Vaccine Biologics Corporation, and Dynavax Technologies Corporation announced the rollout of its COVID-19 vaccine, MVC-COV1901. Approx...

Neutral

Dynavax Technologies Corporation has filed a Sh...

2021-08-04 00:00:00

Dynavax Technologies Corporation has filed a Shelf Registration in the amount of $26.785 million. Security Name: Common Stock Securities O...

Neutral

Dynavax Technologies Corporation to Report Q2, ...

2021-07-21 20:02:00

Dynavax Technologies Corporation announced that they will report Q2, 2021 results After-Market on Aug 04, 2021

Neutral

Dynavax Technologies Corporation, Q2 2021 Earni...

2021-07-21 20:02:00

Dynavax Technologies Corporation, Q2 2021 Earnings Call, Aug 04, 2021

Neutral

Dynavax Technologies Corporation and Biological...

2021-07-06 12:00:00

Dynavax Technologies Corporation and Biological E. Limited announced the execution of a commercial supply agreement of Dynavax'sCpG 1018TM adv...

Neutral

Clover Biopharmaceuticals and Dynavax Technolog...

2021-06-30 08:00:00

Clover Biopharmaceuticals and Dynavax Technologies Corporation announced the execution of a commercial supply agreement of Dynavax's CpG 1018T...

Negative

Dynavax Technologies Corporation Announces Appo...

2021-06-29 20:05:00

Dynavax Technologies Corporation announced appointment of John Slebir as Senior Vice President, General Counsel on June 28, 2021.

Neutral

Dynavax Technologies Corporation has filed a Shelf Registration in the amount of $178.8 million.

2022-06-02 00:00:00

Dynavax Technologies Corporation has filed a Shelf Registration in the amount of $178.8 million. Security Name: Common Stock Securities Offered: 15,000,000 Transaction Features: ESOP Related Offering

Neutral

Dynavax Technologies Corporation Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-06-2022 05:40 PM

2022-05-25 20:05:00

Dynavax Technologies Corporation Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-06-2022 05:40 PM. Venue: Loews Chicago Hotel, Chicago, Illinois, United States. Speakers: Kelly MacDonald, Senior VP & CFO, Ryan Spencer, CEO & Director.

Positive

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P Composite 1500

2022-05-17 00:00:00

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P Composite 1500

Positive

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P 600 Health Care (Sector)

2022-05-17 00:00:00

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P 600 Health Care (Sector)

Positive

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P 1000

2022-05-17 00:00:00

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P 1000

Positive

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P 600

2022-05-17 00:00:00

Dynavax Technologies Corporation(NasdaqCM:DVAX) added to S&P 600

Neutral

Dynavax Technologies Corporation Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM

2022-05-16 20:10:00

Dynavax Technologies Corporation Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States. Speakers: Ryan Spencer, CEO & Director.

Neutral

Dynavax Technologies Corporation Reaffirms Earnings Guidance for the Year 2022

2022-05-05 20:05:00

Dynavax Technologies Corporation reaffirmed earnings guidance for the year 2022. For the full-year CpG 1018 adjuvant net product revenues of at least $550 million, with an associated gross margin of approximately 50%.

Neutral

Dynavax Technologies Corporation to Report Q1, 2022 Results on May 05, 2022

2022-04-21 20:05:00

Dynavax Technologies Corporation announced that they will report Q1, 2022 results After-Market on May 05, 2022

Neutral

Dynavax Technologies Corporation, Q1 2022 Earnings Call, May 05, 2022

2022-04-21 20:05:00

Dynavax Technologies Corporation, Q1 2022 Earnings Call, May 05, 2022

Neutral

Dynavax Technologies Corporation - Shareholder/Analyst Call

2022-04-14 20:17:00

AGM

Neutral

Dynavax Technologies Corporation, Annual General Meeting, May 26, 2022

2022-04-14 20:17:00

Dynavax Technologies Corporation, Annual General Meeting, May 26, 2022, at 09:00 Pacific Standard Time. Agenda: To elect our five nominees for Class I directors to hold office until the 2025 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified; To approve the amendment and restatement of the Dynavax Technologies Corporation 2018 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 15,000,000; To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement accompanying this Notice; and to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.

Negative

Dynavax Technologies Corporation Announces Appointment of Elaine D. Sun to Board of Directors

2021-12-14 13:10:00

Dynavax Technologies Corporation announced the appointment of Elaine Sun to its Board of Directors. Ms. Sun has more than two decades of experience in the investment banking and life sciences industries. Over her career she has led and played key roles in a broad range of transactions, including multiple mergers, acquisitions and financings, valued in excess of $50 billion. Currently she serves as senior vice president and chief financial officer at Halozyme. Prior to Halozyme, she served as chief financial officer and chief strategy officer at SutroVax Inc. (now known as Vaxcyte Inc.), a private biopharmaceutical company developing vaccines to prevent serious infectious diseases. While at SutroVax she provided strategic, operational and financial leadership for a rapidly growing organization, including establishing innovative agreements with external contract manufacturers. Previously, Ms. Sun served as Managing Director and Head of West Coast Healthcare for Evercore Partners and Managing Director at Merrill Lynch & Co. Inc. Ms. Sun previously served on the board of directors of Cirius Therapeutics.

Neutral

Dynavax Technologies Corporation Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 02:40 PM

2021-11-18 21:10:00

Dynavax Technologies Corporation Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 02:40 PM. Speakers: Ryan Spencer, CEO & Director.

Neutral

Dynavax Technologies Corporation Provides Revenue Guidance for the Full Year 2021

2021-11-04 20:50:00

Dynavax Technologies Corporation provided revenue guidance for the full year 2021. For the period, the company expects revenue guidance to be between $375 and $425 million.

Negative

Dynavax Technologies Corporation Announces Board Changes

2021-10-21 20:20:00

Dynavax Technologies Corporation announced the appointment of Scott Myers to its Board of Directors. Mr. Myers was also elected Board Chairman, succeeding Dr. Andrew Hack who has served as interim Chairman of the Board since May 2020. Dr. Hack will continue to serve on the Board of Directors. Most recently he was the Chief Executive Officer and served on the board of directors of AMAG Pharmaceuticals Inc., where he led its turnaround and strategic sale to Covis Pharma, S.à.r.l. in November 2020.

Neutral

Dynavax Technologies Corporation to Report Q3, 2021 Results on Nov 04, 2021

2021-10-21 12:00:00

Dynavax Technologies Corporation announced that they will report Q3, 2021 results After-Market on Nov 04, 2021

Neutral

Dynavax Technologies Corporation, Q3 2021 Earnings Call, Nov 04, 2021

2021-10-21 12:00:00

Dynavax Technologies Corporation, Q3 2021 Earnings Call, Nov 04, 2021

Neutral

Dynavax Technologies Corporation Presents at AASLD The Liver Meeting, Nov-12-2021

2021-10-15 04:09:00

Dynavax Technologies Corporation Presents at AASLD The Liver Meeting, Nov-12-2021 . Speakers: Kelvin McKoy.

Neutral

Dynavax and U.S. Department of Defense Announce Collaboration to Develop an Adjuvanted Plague Vaccine Using Dynavax's Cpg 1018 Adjuvant

2021-10-04 12:00:00

Dynavax Technologies Corporation announced Dynavax has executed an agreement for approximately $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018®. Under the agreement, Dynavax will conduct a Phase 2 clinical trial combining its CpG 1018 adjuvant with the DOD's rF1V vaccine. The Company anticipates the Phase 2 trial will commence in 2022. This agreement, funded by the DOD'sJoint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), enables Dynavax to conduct a Phase 2 clinical trial, submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), and generate additional clinical trial results to add to the existing clinical and non-clinical data. Any future commercial supply agreements would be subject to a separate agreement between Dynavax and the U.S government. The planned Phase 2 randomized, placebo-controlled, observer-blind, multicenter clinical trial will evaluate the immunogenicity, safety, and tolerability of the rF1V vaccine antigens provided by the U.S. government combined with Dynavax's CpG 1018 adjuvant in adults 18 to 55 years of age.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct 13, 2021

2021-09-27 20:20:00

H.C. Wainwright & Co., LLC, H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct 13, 2021.

Neutral

Dynavax Technologies Corporation Presents at Guggenheim 2nd Annual Vaccine and Infectious Disease Days, Oct-05-2021 12:00 PM

2021-09-27 20:20:00

Dynavax Technologies Corporation Presents at Guggenheim 2nd Annual Vaccine and Infectious Disease Days, Oct-05-2021 12:00 PM.

Neutral

Dynavax Technologies Corporation Presents at H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct-13-2021 12:00 PM

2021-09-27 20:20:00

Dynavax Technologies Corporation Presents at H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct-13-2021 12:00 PM.

Neutral

Dynavax Technologies Corporation Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 12:00 PM

2021-09-23 22:02:00

Dynavax Technologies Corporation Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 12:00 PM. Venue: New York, United States. Speakers: Kelly MacDonald, Senior VP & CFO, Ryan Spencer, CEO & Director.

Neutral

COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial

2021-09-22 11:08:00

Dynavax Technologies Corporation announced that Clover Biopharmaceuticals (Clover) reported positive data for their protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) adjuvanted with Dynavax's CpG 1018 adjuvant, which achieved the primary and secondary efficacy endpoints in SPECTRA, a global pivotal Phase 2/3 clinical trial that enrolled over 30,000 participants. Vaccine efficacy was successfully demonstrated in an environment where 100% of SARS-CoV-2 strains observed in the efficacy analysis were variants. Clover reported the following data from their Phase 2/3 SPECTRA trial in a press release issued September 22, 2021. SCB-2019 (CpG 1018/Alum) demonstrated 100% efficacy against severe COVID-19 and hospitalizations and 84% efficacy against moderate-to-severe COVID-19 caused by any strain of SARS-CoV-2. SCB-2019 (CpG 1018/Alum) demonstrated 79% overall efficacy against COVID-19 of any severity caused by the globally dominant Delta variant. Efficacy was 92% against the Gamma variant and 59% against the Mu variant, and collectively these three strains (Delta, Gamma and Mu) comprised 73% of all strains identified in the study. Overall efficacy was 67% against COVID-19 of any severity caused by any strain in the study, successfully meeting the primary endpoint of the trial. Clover's vaccine candidate is one of the first to demonstrate significant efficacy against Delta in a double-blind, randomized clinical trial. SCB-2019 (CpG 1018/Alum) demonstrated a favorable safety profile. Severe and serious adverse events (AEs) were infrequent and balanced between vaccine and placebo groups. Solicited local AEs were mostly mild and transient cases of pain at the injection site and decreased in frequency after the second dose. Importantly, the frequency of solicited systemic AEs monitored (fatigue, headache, muscle pain, joint pain, loss of appetite, nausea, chills, fever), were similar between vaccine and placebo groups. Additional data from the SPECTRA final analysis have been made available in a presentation that can be found on Clover's corporate website. Clover intends to submit the trial results for peer-reviewed publication. Clover plans to submit conditional approval applications to global regulatory authorities including China'sNational Medical Products Administration, the European Medicines Agency, and the World Health Organization (WHO) in the fourth quarter of 2021. Contingent upon receiving a conditional approval, Clover plans to commence initial product launch of SCB-2019 (CpG 1018/Alum) potentially by the end of 2021. Subject to receiving Emergency Use Listing (EUL) from the WHO, Clover plans to supply up to 414 million doses of its COVID-19 vaccine candidate globally through the COVAX Facility as previously announced. SPECTRA (Study Evaluating Protective-Efficacy and Safety of Clover's Trimeric Recombinant Protein-based and Adjuvanted COVID-19 Vaccine) is Clover's double-blind, randomized, placebo-controlled study of SCB-2019 (CpG 1018/Alum) administered in a two-dose regimen, 21 days apart. Global enrollment surpassed 30,000 participants aged 18 years or older in five countries across four continents resulting in one of the most ethnically diverse COVID-19 clinical trials conducted to date, including 49% of participants from Asia, 45% from Latin America and the remainder from Europe and Africa. CpG 1018 is the adjuvant used in HEPLISAV-B. Dynavax developed CpG 1018 adjuvant to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B. CpG 1018 adjuvant provides a well- developed technology and a significant safety database, potentially accelerating the development and large-scale manufacturing of a COVID-19 vaccine.

Neutral

American Association For The Study Of Liver Diseases, AASLD the Liver Meeting, Nov 12, 2021 through Nov 15, 2021

2021-09-20 00:00:00

American Association For The Study Of Liver Diseases, AASLD The Liver Meeting, Nov 12, 2021 through Nov 15, 2021.

Neutral

Dynavax Technologies Corporation Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-10 02:36:00

Dynavax Technologies Corporation Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Ryan Spencer, CEO & Director.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation Announces Launch of Its Covid-19 Vaccine Mvc-Cov1901 Adjuvanted with Dynavax's Cpg 1018 Adjuvant

2021-08-23 12:00:00

Medigen Vaccine Biologics Corporation, and Dynavax Technologies Corporation announced the rollout of its COVID-19 vaccine, MVC-COV1901. Approximately 600,000 people are anticipated to receive the Medigen vaccine this week. MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax and aluminum hydroxide. The S-2P antigen is a trimeric and prefusion-stable recombinant spike protein developed by the U.S.NIH. MVC has obtained a global technology license for S-2P from the U.S. Vaccine Research Center at National Institutes of Health (NIH). MVC-COV1901 vaccine's Phase 1 and 3,815-participant Phase 2 clinical study data has shown robust safety and promising immunogenicity responses and as a result obtained Taiwan's EUA approval on July 19th, 2021. MVC will continue to collaborate with international partners for phase 3 clinical trial development and assist the global community in its fight against the COVID-19 pandemic.

Neutral

Dynavax Technologies Corporation has filed a Shelf Registration in the amount of $26.785 million.

2021-08-04 00:00:00

Dynavax Technologies Corporation has filed a Shelf Registration in the amount of $26.785 million. Security Name: Common Stock Securities Offered: 2,750,000 Transaction Features: ESOP Related Offering

Neutral

Dynavax Technologies Corporation to Report Q2, 2021 Results on Aug 04, 2021

2021-07-21 20:02:00

Dynavax Technologies Corporation announced that they will report Q2, 2021 results After-Market on Aug 04, 2021

Neutral

Dynavax Technologies Corporation, Q2 2021 Earnings Call, Aug 04, 2021

2021-07-21 20:02:00

Dynavax Technologies Corporation, Q2 2021 Earnings Call, Aug 04, 2021

Neutral

Dynavax Technologies Corporation and Biological E. Limited Announce Commercial Supply Agreement of Dynavax's CPG 1018 Adjuvant for Biological E's Covid-19 Vaccine Candidate

2021-07-06 12:00:00

Dynavax Technologies Corporation and Biological E. Limited announced the execution of a commercial supply agreement of Dynavax'sCpG 1018TM advanced adjuvant, for use in BE's subunit COVID-19 vaccine candidate, CORBEVAX™. The commercial supply agreement extends through 2022. The agreement includes doses for delivery in 2021, which were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax. Pending conditional regulatory approvals in India, BE expects to commence product launch of CORBEVAX™ later this year. In June 2021, India'sUnion Ministry of Health announced that it had finalized arrangements with BE to reserve 300 million doses of CORBEVAX™. The arrangement with BE is part of the wider endeavor from the Government of India to encourage indigenous vaccine manufacturers by providing financial support.

Neutral

Clover Biopharmaceuticals and Dynavax Technologies Corporation Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate

2021-06-30 08:00:00

Clover Biopharmaceuticals and Dynavax Technologies Corporation announced the execution of a commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant, for use in Clover's protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum). The commercial supply agreement extends to the end of 2022. The agreement includes doses for delivery in 2021, which were manufactured under the previously announced funding agreement between Coalition for Epidemic Preparedness Innovations and the company. Employing the Trimer-Tag technology platform, Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus. Clover's COVID-19 vaccine candidate is the combination of SCB-2019 and two adjuvants, the company's CpG 1018 advanced adjuvant and aluminum hydroxide. Clover is currently advancing SPECTRA, a global pivotal Phase 2/3 clinical trial evaluating the efficacy, safety, and immunogenicity of SCB-2019, and expects interim data for vaccine efficacy around the middle of 2021. Pending positive interim data, Clover plans to submit conditional regulatory approval applications to the EMA, the NMPA and the WHO in the second half of 2021, and plans to commence product launch by the end of 2021.

Negative

Dynavax Technologies Corporation Announces Appointment of John Slebir as Senior Vice President, General Counsel

2021-06-29 20:05:00

Dynavax Technologies Corporation announced appointment of John Slebir as Senior Vice President, General Counsel on June 28, 2021.

Fundamental Summary

Dynavax's financial results from Q1 demonstrated decent performance but will likely only help Dynavax remain on par with its peers. We do believe, though, that macro-related market conditions will influence the stock's performance more significantly than its individual results. As such, Dynavax received an overall score of 64 and a HOLD recommendation.

Dynavax reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 113.99 million compared to USD 83.34 million a year ago. Net income was USD 32.86 million compared to USD 0.891 million a year ago. Basic earnings per share from continuing operations was USD 0.26 compared to USD 0.01 a year ago. Diluted earnings per share from continuing operations was USD 0.22 compared to USD 0.01 a year ago.

Business Description

Dynavax, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax in September 1996. Dynavax was incorporated in 1996 and is headquartered in Emeryville, California.

Sector Overview

Dynavax is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Dynavax's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 1,009.0 -2.9% 69
Liabilities 721.5 -11.7% 52
Price to Book 4.5 -41.8% 76
Cash & Equivalents 179.4 -58.9% 38
Equity 287.5 29.3% 54
EBITDA 153.8 1.2% 69
Total Revenues 468.9 7.0% 51
Parameter Value Change Score
Return on Equity 56.1 2.8% 77
Net Cashflow 100.4 -75.2% 64
Capital Expenditure -8.1 4.6% 82
Asset Turnover 0.6 -0.6% 65
Free Cashflow 2.0 -28.9% 48

* All values are TTM

The below chart reflects Dynavax's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Dynavax's peer average final assessment score stands on 64.0, Dynavax's score is 64.

  •  DVAX
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 0 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 1 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 2 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 3 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 5 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 6 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 7 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 8 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 9 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 10 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 11 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 12 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 13 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 14 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 15 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 16 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 17 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 18 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 20 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 21 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 22 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 24 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 25 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 26 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 27 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 28 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 29 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 30 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 32 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 33 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 34 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 35 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 36 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 37 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 39 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 40 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 41 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 42 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 43 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 44 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 45 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 47 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 48 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 50 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 51 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 54 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 55 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 56 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 57 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 59 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 60 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 61 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 62 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 63 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 64 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 65 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 66 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 68 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 69 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 73 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 74 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 75 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 76 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 77 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 80 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 81 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 82 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 83 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 84 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 86 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 87 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 88 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Dynavax's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Dynavax's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 68.

Neutral 68
Close Price 12.17
52W Low 7.45
52W High 20.94
5D MA 12.16
50D MA 10.52
200D MA 13.38
MACD 0.34
RSI 14.42
STOCH 86.22

Balance Sheet Analysis

Two metrics jump up as the most significant positive drivers of the balance sheet strength in Dynavaxs recent report: Book Value Factors and Assets. Dynavax publishes solid book value factor metrics in this report. Price to book ratio (P/B) now sits at 4.5 and represents a -41.8% change from the previous report. The company's book value factor metrics are even more remarkable when compared to their peers. Therefore, its book value factors earned a score of 76. Also, Dynavax assets on their balance sheet, moved to 1009.0, which is a -2.9% change from the last period. This performance is interesting in comparison to its peers and competitors. Therefore, its asset component earned a score of 69. On the other hand, Cash & Equivalents, jumped out as looking rather underwhelming. Dynavax reported concerning cash and cash equivalents metrics in this filing. Specifically, they reported that cash and cash equivalents were 179.4, representing a -58.9% change from the last period. This performance is significantly less impressive than its peers and competitors. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their cash and cash equivalents with a score of 38. Therefore, we scored its balance sheet a 63.

Parameter Value Change Score
Assets 1,009.0 -2.9% 69
Liabilities 721.5 -11.7% 52
Price to Book 4.5 -41.8% 76
Cash & Equivalents 179.4 -58.9% 38
Equity 287.5 29.3% 54
* All values are TTM

The below chart describes Dynavax's performance as reflected on its balance sheet with respect to its peers. While Dynavax received a balance sheet score of 63, the average of its peers stands on 63.0.

  •  DVAX
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 0 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 1 1
Vericel Corporation 1.1B 51 65 56 53 61 57 2 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 3 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 5 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 6 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 7 1
Immatics N.V. 538.7M 56 70 84 95 73 76 8 1
Agenus Inc. 520.5M 73 62 37 55 60 54 9 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 10 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 11 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 12 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 13 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 14 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 15 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 16 1
Amgen Inc. 130.1B 72 68 86 53 62 69 17 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 18 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 20 1
BioNTech SE 34.0B 75 69 64 97 73 75 21 1
Seagen Inc. 32.9B 59 68 55 43 66 61 22 1
Biogen Inc. 29.7B 57 72 92 50 76 76 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 24 1
Incyte Corporation 16.8B 71 72 95 82 79 83 25 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 26 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 27 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 28 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 29 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 30 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 31 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 32 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 33 1
Alkermes plc 5.0B 63 66 46 54 71 62 34 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 35 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 36 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 37 1
Natera, Inc. 3.6B 73 65 43 95 42 54 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 39 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 40 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 41 1
CureVac N.V. 2.6B 49 64 75 52 52 57 42 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 43 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 44 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 45 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 47 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 48 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 50 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 51 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 54 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 55 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 56 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 57 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 59 1
CareDx, Inc 1.2B 54 67 52 39 51 52 60 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 61 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 62 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 63 1
MannKind Corporation 957.2M 79 59 50 40 64 57 64 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 65 1
Merus N.V. 941.6M 59 68 50 83 81 70 66 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 68 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 69 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 73 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 74 1
Geron Corporation 566.2M 69 72 37 59 62 60 75 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 76 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 77 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
Affimed N.V. 415.0M 56 66 63 56 47 54 80 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 81 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 82 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 83 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 84 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 86 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 87 1
AC Immune SA 299.8M 84 64 47 53 75 68 88 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Dynavax appears likely to maintain its strong income statement metrics and momentum going forward. Dynavax's reported return on equity (ROE) ratio was 56.1, representing a change of 2.8%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Therefore, its return factors component earned a score of 77. Also, Dynavax reported impressive EBITDA this period. At filing, EBITDA was reported as 153.8, representing 1.2% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. The company is headed in the right direction regarding EBITDA, exhibiting efficient capital controls and strong overall financial performance. Consequently, their EBITDA movement received a grade of 69. On the other hand, Revenue Efficiency, jumped out as looking rather underwhelming. Dynavax management did an underwhelming job managing revenue efficiency this past period. Dynavax's revenue efficiency is 468.9 according to the metrics in the current filing, which represents a 7.0% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. As a result, their revenue efficiency earned a score of 51. Therefore, it received a score of 67.

Parameter Value Change Score
EBITDA 153.8 1.2% 69
Total Revenues 468.9 7.0% 51
Return on Equity 56.1 2.8% 77
* All values are TTM

The below chart describes Dynavax's performance as reflected on its income statement with respect to its peers. While Dynavax received a income statement score of 67 , the average of its peers stands on 67.0.

  •  DVAX
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Exact Sciences Corporation 7.2B 57 67 54 62 0 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 1 1
Vericel Corporation 1.1B 76 44 82 56 2 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 3 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 5 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 6 1
CTI BioPharma Corp. 603.6M 84 50 62 59 7 1
Immatics N.V. 538.7M 37 93 53 77 8 1
Agenus Inc. 520.5M 57 83 45 74 9 1
Vaxart, Inc. 440.0M 99 51 72 68 10 1
MiMedx Group, Inc. 391.5M 87 43 83 59 11 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 12 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 13 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 14 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 15 1
DermTech, Inc. 165.3M 49 48 78 52 16 1
Amgen Inc. 130.1B 74 75 64 78 17 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 18 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 20 1
BioNTech SE 34.0B 41 89 75 79 21 1
Seagen Inc. 32.9B 54 65 70 62 22 1
Biogen Inc. 29.7B 90 57 73 70 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 24 1
Incyte Corporation 16.8B 59 77 60 73 25 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 26 1
United Therapeutics Corporation 10.6B 57 91 54 82 27 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 28 1
Exelixis, Inc. 6.7B 54 91 54 81 29 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 30 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 32 1
Ascendis Pharma A/S 5.2B 38 68 46 54 33 1
Alkermes plc 5.0B 69 55 81 62 34 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 35 1
Novavax, Inc. 4.0B 41 89 54 75 36 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 37 1
Natera, Inc. 3.6B 52 51 78 52 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 39 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 40 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 41 1
CureVac N.V. 2.6B 45 83 71 74 42 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 43 1
Insmed Incorporated 2.4B 51 58 73 57 44 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 45 1
Abgenix Inc. 2.1B 47 47 47 47 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 47 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 48 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 50 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 51 1
Xencor, Inc. 1.6B 42 94 52 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 54 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 55 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 56 1
Veracyte, Inc. 1.4B 45 63 57 55 57 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 58 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 59 1
CareDx, Inc 1.2B 61 44 82 50 60 1
IVERIC bio, Inc. 1.1B 84 58 79 70 61 1
FibroGen, Inc. 1.0B 48 74 63 67 62 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 63 1
MannKind Corporation 957.2M 95 48 56 61 64 1
ImmunoGen, Inc. 946.1M 40 73 71 64 65 1
Merus N.V. 941.6M 48 60 59 54 66 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 68 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 69 1
Amarin Corporation plc 734.5M 95 44 82 63 70 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 73 1
AnaptysBio, Inc. 586.3M 97 50 77 68 74 1
Geron Corporation 566.2M 89 67 73 78 75 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 76 1
Radius Health, Inc. 499.8M 94 71 68 82 77 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
Affimed N.V. 415.0M 95 49 75 66 80 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 81 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 82 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 83 1
Zymeworks Inc. 324.7M 58 53 77 56 84 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 86 1
Silence Therapeutics plc 313.4M 83 64 69 72 87 1
AC Immune SA 299.8M 83 61 65 70 88 1
Precigen, Inc. 299.1M 57 87 59 79 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Two main cash flow metrics, Capex and Asset Turnover, are driving the positive outlook for Dynavax's financial strength. Dynavax's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -8.1, which represents a 4.6% change from the last period. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their CapEx movement received a grade of 82. Also, Dynavax's published asset turnover numbers were encouraging and reflected management's balanced change strategy. Dynavax recorded asset turnover of 0.6, which represents a -0.6% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Its asset turnover metrics are especially remarkable relative to their peers. We believe the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its asset turnover movement earned a score of 65. On the other hand, Free Cash flow, jumped out as looking problematic. Dynavax did a poor job related to generating and maintaining strong free cash flow this period, which stood at 2.0, representing a -28.9% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 2.6 percent by this parameter. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Its free cash flow movement, therefore, received a grade of 48. Their cash flow, therefore, earned a score of 68.

Parameter Value Change Score
Net Cashflow 100.4 -75.2% 64
Capital Expenditure -8.1 4.6% 82
Asset Turnover 0.6 -0.6% 65
Free Cashflow 2.0 -28.9% 48
* All values are TTM

The below chart describes Dynavax's performance as reflected on its cash flow with respect to its peers. While Dynavax received a cash flow score of 68, the average of its peers stands on 69.0.

  •  DVAX
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Exact Sciences Corporation 7.2B 53 45 80 46 56 0 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 1 1
Vericel Corporation 1.1B 64 46 59 73 65 2 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 3 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 5 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 6 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 7 1
Immatics N.V. 538.7M 82 95 56 99 86 8 1
Agenus Inc. 520.5M 57 43 52 77 58 9 1
Vaxart, Inc. 440.0M 72 56 53 38 65 10 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 11 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 12 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 13 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 14 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 15 1
DermTech, Inc. 165.3M 60 51 45 86 58 16 1
Amgen Inc. 130.1B 80 74 67 74 81 17 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 18 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 20 1
BioNTech SE 34.0B 73 97 50 52 72 21 1
Seagen Inc. 32.9B 53 53 50 87 58 22 1
Biogen Inc. 29.7B 58 54 90 73 66 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 24 1
Incyte Corporation 16.8B 78 79 92 74 84 25 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 26 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 27 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 28 1
Exelixis, Inc. 6.7B 79 90 89 83 87 29 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 30 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 31 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 32 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 33 1
Alkermes plc 5.0B 89 95 76 80 92 34 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 35 1
Novavax, Inc. 4.0B 62 38 63 54 60 36 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 37 1
Natera, Inc. 3.6B 52 54 56 84 58 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 39 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 40 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 41 1
CureVac N.V. 2.6B 87 80 90 70 90 42 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 43 1
Insmed Incorporated 2.4B 79 80 61 89 82 44 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 45 1
Abgenix Inc. 2.1B 66 53 45 59 58 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 47 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 48 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 50 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 51 1
Xencor, Inc. 1.6B 96 95 70 95 98 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 54 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 55 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 56 1
Veracyte, Inc. 1.4B 90 95 46 46 82 57 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 58 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 59 1
CareDx, Inc 1.2B 98 84 40 50 86 60 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 61 1
FibroGen, Inc. 1.0B 86 74 48 87 84 62 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 63 1
MannKind Corporation 957.2M 77 56 43 37 66 64 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 65 1
Merus N.V. 941.6M 70 71 74 53 71 66 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 68 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 69 1
Amarin Corporation plc 734.5M 52 40 74 55 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 73 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 74 1
Geron Corporation 566.2M 78 68 49 81 77 75 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 76 1
Radius Health, Inc. 499.8M 64 40 37 56 57 77 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
Affimed N.V. 415.0M 72 57 95 43 74 80 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 81 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 82 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 83 1
Zymeworks Inc. 324.7M 52 65 45 83 57 84 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 86 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 87 1
AC Immune SA 299.8M 66 77 79 63 68 88 1
Precigen, Inc. 299.1M 82 75 37 85 74 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.